CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Nadda expressed his concern about growing incidence of Non-Communicable Diseases and the importance of awareness regarding healthy diet and lifestyle
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
Greg was also central to the planning, design, and construction of this facility
Subscribe To Our Newsletter & Stay Updated
